Last reviewed · How we verify
LY3549492
At a glance
| Generic name | LY3549492 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (PHASE2)
- A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants (PHASE1)
- A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight (PHASE2)
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or Obesity (PHASE1)
- A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus (PHASE1)
- A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes (PHASE2)
- A Study of LY3549492 in Healthy Weight Adult Participants (PHASE2)
- A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |